tradingkey.logo

Pluri Inc

PLUR
View Detailed Chart
3.470USD
-0.180-4.93%
Close 02/06, 16:00ETQuotes delayed by 15 min
28.32MMarket Cap
LossP/E TTM

Pluri Inc

3.470
-0.180-4.93%
Intraday
1m
30m
1h
D
W
M
D

Today

-4.93%

5 Days

-0.29%

1 Month

+18.84%

6 Months

-30.81%

Year to Date

+16.05%

1 Year

-24.07%

View Detailed Chart

TradingKey Stock Score of Pluri Inc

Currency: USD Updated: 2026-02-06

Key Insights

Pluri Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 155 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.00.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Pluri Inc's Score

Industry at a Glance

Industry Ranking
155 / 392
Overall Ranking
302 / 4521
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Pluri Inc Highlights

StrengthsRisks
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 365.51% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.34M.
Fairly Valued
The company’s latest PE is -1.11, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.37M shares, decreasing 2.95% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 33.92K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.76.

Analyst Rating

Based on 1 analysts
Buy
Current Rating
12.000
Target Price
+228.77%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Pluri Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Pluri Inc Info

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Ticker SymbolPLUR
CompanyPluri Inc
CEOYanay (Yaky)
Websitehttps://pluri-biotech.com/
KeyAI